TY - JOUR
T1 - Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome
AU - Inohara, Taku
AU - Pieper, Karen
AU - Wojdyla, Daniel M.
AU - Patel, Manesh R.
AU - Jones, William Schuyler
AU - Tricoci, Pierluigi
AU - Mahaffey, Kenneth W.
AU - James, Stefan K.
AU - Alexander, John H.
AU - Lopes, Renato D.
AU - Wallentin, Lars
AU - Ohman, Erik Magnus
AU - Roe, Matthew T.
AU - Vemulapalli, Sreekanth
N1 - Funding Information:
Dr Taku Inohara discloses the following relationships—research grant: JSPS Overseas Research fellowship and Boston Scientific. Dr Manesh R. Patel discloses the following relationships—research grant: Heart Flow Technologies, Jansen, Johnson & Johnson, Astra Zeneca, and AHRQ; consultant/advisory board: Astra Zeneca, Bayer, and Otsuka. Dr W. Schuyler Jones discloses the following relationships—research grant: Agency for Healthcare Research and Quality, American Heart Association, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, and Patient Centered Outcomes Research Institute. Dr Pierluigi Tricoci discloses the following relationships—research grant: Amgen, Merck&Co., Sanofi-Aventis, CSL, and Regeneron. Dr Kenneth W. Mahaffey discloses the following relationships—research grant: AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Portola, POZEN Pharmaceutical, Schering-Plough; consultant/advisory board: Modest, Amgen, AstraZeneca, Glaxo SmithKline, Johnson & Johnson, and Merck. Dr Stefan K. James discloses the following relationships—institutional research grant: AstraZeneca, Medtronic, and The Medicines Company; honoraria: AstraZeneca and The Medicines Company; consultant/advisory board: AstraZeneca, Medtronic, and Bayer Janssen. Dr John H. Alexander discloses the following relationships—AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, CSL Behring, Sanofi, and Tenax Therapeutics; consultant/advisory board: Cempra, CryoLife, CSL Behring, Pfizer, Portola Pharmaceuticals, and VasoPrep Surgical. Dr Renato D. Lopes discloses Institutional research grants from Bristol-Myers Squibb and GlaxoSmithKline and consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Portola. Dr Lars Wallentin discloses the following relationships—institutional research grant: Bristol-Myers Squibb/Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck & Co, and Roche Diagnostics; consultant/lecturer: Bristol-Myers Squibb/Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Abbott; travel support: Bristol-Myers Squibb/Pfizer, AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim. Dr E. Magnus Ohman discloses the following relationships—research grant: Daiichi Sankyo, Eli Lilly, and Gilead Sciences; speakers bureau: Gilead Sciences, Boehringer Ingelheim, and The Medicines Company; consultant/advisory board: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Liposcience, Merck, Pozen, Hoffmann-La Roche, Sanofi-Aventis, The Medicines Company, and Web MD. Dr Matthew Roe discloses the following relationships—research grant: Eli Lilly, Sanofi, Daiichi-Sankyo, Janssen Pharmaceuticals, Ferring Pharmaceuticals, Myokardia, and AstraZeneca; consultant/advisory board: PriMed, AstraZeneca, Boehringer Ingelheim, Merck, Acetlion, Amgen, Myokardia, Eli Lilly, Novartis, Daiichi-Sankyo, Quest Diagnostics, and Elsevier Publishers. Dr Sreekanth Vemulapalli discloses the following relationships—research grant: American College of Cardiology, Abbott Vascular, Agency for Healthcare Research and Quality, Patient Centered Outcomes Research Institute, Society of Thoracic Surgeons, and Boston Scientific; consultant/advisory board: Premiere Research, Janssen, Boston Scientific, and Novella. No other authors have any conflicts to disclose.
Funding Information:
This manuscript was funded by investigator discretionary research dollars and JSPS Overseas Research fellowship. Funding for the creation of the combined ACS database was provided by AstraZeneca . The TRILOGY ACS study was funded by Daiichi Sankyo and Eli Lilly. PLATO was funded by AstraZeneca; APPRAISE-2 was funded by Bristol-Myers Squibb and Pfizer; and TRACER was funded by Merck & Co. The study sponsors had no role in the conception and design of this study or in creating the first draft of the manuscript.
Publisher Copyright:
© 2018
PY - 2018/7
Y1 - 2018/7
N2 - Background: Patients with peripheral artery disease (PAD) are known to have an increased risk of ischemic cardiovascular events. However, the influence of concomitant PAD on first and subsequent recurrent ischemic events after an acute coronary syndrome (ACS) remains poorly characterized. Methods: We analyzed the combined data set from 4 randomized trials (PLATO, APPRAISE-2, TRA-CER, and TRILOGY ACS) in ACS for a follow-up length of 1 year. Using multivariable regression, we examined the association between PAD and major adverse cardiovascular events, a composite of cardiovascular death, myocardial infarction, and stroke. Among patients with a nonfatal first event, we evaluated the incidence and type of a second recurrent event. Results: A total of 4,098 of 48,094 (8.5%) post-ACS patients had a history of PAD. The unadjusted frequency of major adverse cardiovascular events was 2-fold higher in patients with PAD (14.3% vs 7.5%) over a median (25th-75th) follow-up of 353 (223-365) days with an adjusted hazard ratio of 1.63 (95% CI: 1.48-1.78; P <.001). The frequency of recurrent ischemic events among those patients with a first, nonfatal event was higher among those with PAD (40.0% vs 27.7%). The relative frequency of each event type (cardiovascular death, noncardiovascular death, myocardial infarction, or stroke) within first and subsequent ischemic events was similar regardless of PAD status at baseline. Conclusions: Patients with PAD have a significantly higher risk of first and recurrent ischemic events in the post-ACS setting. These findings highlight the opportunity for improved treatments in patients with PAD who experience an ACS.
AB - Background: Patients with peripheral artery disease (PAD) are known to have an increased risk of ischemic cardiovascular events. However, the influence of concomitant PAD on first and subsequent recurrent ischemic events after an acute coronary syndrome (ACS) remains poorly characterized. Methods: We analyzed the combined data set from 4 randomized trials (PLATO, APPRAISE-2, TRA-CER, and TRILOGY ACS) in ACS for a follow-up length of 1 year. Using multivariable regression, we examined the association between PAD and major adverse cardiovascular events, a composite of cardiovascular death, myocardial infarction, and stroke. Among patients with a nonfatal first event, we evaluated the incidence and type of a second recurrent event. Results: A total of 4,098 of 48,094 (8.5%) post-ACS patients had a history of PAD. The unadjusted frequency of major adverse cardiovascular events was 2-fold higher in patients with PAD (14.3% vs 7.5%) over a median (25th-75th) follow-up of 353 (223-365) days with an adjusted hazard ratio of 1.63 (95% CI: 1.48-1.78; P <.001). The frequency of recurrent ischemic events among those patients with a first, nonfatal event was higher among those with PAD (40.0% vs 27.7%). The relative frequency of each event type (cardiovascular death, noncardiovascular death, myocardial infarction, or stroke) within first and subsequent ischemic events was similar regardless of PAD status at baseline. Conclusions: Patients with PAD have a significantly higher risk of first and recurrent ischemic events in the post-ACS setting. These findings highlight the opportunity for improved treatments in patients with PAD who experience an ACS.
UR - http://www.scopus.com/inward/record.url?scp=85046147402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046147402&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2018.03.013
DO - 10.1016/j.ahj.2018.03.013
M3 - Article
C2 - 29910052
AN - SCOPUS:85046147402
SN - 0002-8703
VL - 201
SP - 25
EP - 32
JO - American Heart Journal
JF - American Heart Journal
ER -